Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05309668 · OUTCOME

Selumetinib and N-desmethyl Selumetinib RacAUC0-12 Derived After Multiple Dose Administration

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN · Source last updated 2026-08-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
Ratio
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Pre-dose, 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)

What was measured

To further evaluate the PK of the granule formulation.

Analysis population: Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.

Groups in this outcome

Global Cohort 1

Global Cohort 1 (\>=4 to \<7 years)

Global Cohort 2

Global Cohort 2 (\>=1 to \<4 years)

Total in Global

Global Cohorts (\>=1 to \<7 years)

Japan Cohort

Japan Cohort (\>=1 to \<7 years)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Global Cohort 115
Global Cohort 217
Total in Global32
Japan Cohort4

Reported measurements

Cycle 2 Day 1: Selumetinib

Analysis denominator · Participants

GroupSource count
Global Cohort 114
Global Cohort 213
Total in Global27
Japan Cohort4
Values in Ratio · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Global Cohort 11.64154.51Not reportedNot reportedNot reported
Global Cohort 21.28961.20Not reportedNot reportedNot reported
Total in Global1.46158.23Not reportedNot reportedNot reported
Japan Cohort1.27953.18Not reportedNot reportedNot reported
Cycle 2 Day 1: N-desmethyl selumetinib

Analysis denominator · Participants

GroupSource count
Global Cohort 113
Global Cohort 211
Total in Global24
Japan Cohort4
Values in Ratio · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Global Cohort 11.22135.39Not reportedNot reportedNot reported
Global Cohort 21.09953.72Not reportedNot reportedNot reported
Total in Global1.16343.69Not reportedNot reportedNot reported
Japan Cohort1.21323.76Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        54.51
        value
        1.641
      2. group Id
        OG001
        spread
        61.20
        value
        1.289
      3. group Id
        OG002
        spread
        58.23
        value
        1.461
      4. group Id
        OG003
        spread
        53.18
        value
        1.279
    denoms
    1. counts
      1. group Id
        OG000
        value
        14
      2. group Id
        OG001
        value
        13
      3. group Id
        OG002
        value
        27
      4. group Id
        OG003
        value
        4
      units
      Participants
    title
    Cycle 2 Day 1: Selumetinib
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        35.39
        value
        1.221
      2. group Id
        OG001
        spread
        53.72
        value
        1.099
      3. group Id
        OG002
        spread
        43.69
        value
        1.163
      4. group Id
        OG003
        spread
        23.76
        value
        1.213
    denoms
    1. counts
      1. group Id
        OG000
        value
        13
      2. group Id
        OG001
        value
        11
      3. group Id
        OG002
        value
        24
      4. group Id
        OG003
        value
        4
      units
      Participants
    title
    Cycle 2 Day 1: N-desmethyl selumetinib
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    2. group Id
      OG001
      value
      17
    3. group Id
      OG002
      value
      32
    4. group Id
      OG003
      value
      4
    units
    Participants
description
To further evaluate the PK of the granule formulation.
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Global Cohort 1 (\>=4 to \<7 years)
    id
    OG000
    title
    Global Cohort 1
  2. description
    Global Cohort 2 (\>=1 to \<4 years)
    id
    OG001
    title
    Global Cohort 2
  3. description
    Global Cohorts (\>=1 to \<7 years)
    id
    OG002
    title
    Total in Global
  4. description
    Japan Cohort (\>=1 to \<7 years)
    id
    OG003
    title
    Japan Cohort
param Type
GEOMETRIC_MEAN
population Description
Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.
reporting Status
POSTED
time Frame
Pre-dose, 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)
title
Selumetinib and N-desmethyl Selumetinib RacAUC0-12 Derived After Multiple Dose Administration
type
SECONDARY
unit Of Measure
Ratio

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice